Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an announcement.
Atomo Diagnostics plans to issue up to 30,303,030 new ordinary shares and 15,151,515 options under a securities purchase plan, with options exercisable at $0.045 and expiring 2.5 years from issue. The offer has a record date of 27 March 2026, will close on 8 May 2026, and the securities are scheduled to be issued on 13 May 2026.
Separately, the company intends to conduct a placement of up to 90,909,091 new ordinary shares and 45,454,540 options on similar terms, with a proposed issue date of 7 April 2026. The combined capital raising is set to significantly expand Atomo’s equity base and may provide additional funding capacity for its diagnostics operations and growth initiatives, though it will also dilute existing shareholders.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. is an Australian-listed medical diagnostics company that develops and supplies rapid diagnostic test devices. Its primary products focus on easy-to-use, point-of-care testing solutions, targeting healthcare providers and consumers seeking quick and reliable diagnostic results in both clinical and remote settings.
Average Trading Volume: 1,633,680
Technical Sentiment Signal: Buy
Current Market Cap: A$32.41M
Find detailed analytics on AT1 stock on TipRanks’ Stock Analysis page.